Anti-coagulant aptamers.

In the past decade development of aptamer technology is poised into several fields with various clinical applications. With this progress, aptamer based anti-coagulant agents are evolved and continuing their applications with clinical trials. At present several anti-coagulant aptamers are available against different proteins from blood coagulation cascade. In this review, the mechanism and functions of anti-coagulant aptamers, as an alternate candidate to other available anti-coagulant agents are discussed.

[1]  Mark F. Kubik,et al.  High-affinity RNA ligands to human alpha-thrombin , 1994, Nucleic Acids Res..

[2]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[3]  Subash C B Gopinath,et al.  A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway , 2006, Thrombosis and Haemostasis.

[4]  Steven A Soper,et al.  Designing highly specific biosensing surfaces using aptamer monolayers on gold. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[5]  Brian K Adler,et al.  Unfractionated Heparin and Other Antithrombin Mediated Anticoagulants , 2004, American Society for Clinical Laboratory Science.

[6]  A. Heckel,et al.  Light regulation of aptamer activity: an anti-thrombin aptamer with caged thymidine nucleobases. , 2005, Journal of the American Chemical Society.

[7]  Koji Sode,et al.  Novel electrochemical sensor system for protein using the aptamers in sandwich manner. , 2005, Biosensors & bioelectronics.

[8]  M. Bowser,et al.  In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. , 2004, Analytical chemistry.

[9]  A. Tulinsky,et al.  The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. , 1994, The Journal of biological chemistry.

[10]  A. Schmidt,et al.  Structure-function relationships in factor IX and factor IXa. , 2003, Trends in cardiovascular medicine.

[11]  F. Church,et al.  Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin , 2000, FEBS letters.

[12]  J. Latham,et al.  The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. , 1994, Nucleic acids research.

[13]  P. Urvil,et al.  Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function , 1998 .

[14]  Y. Komatsu,et al.  New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX , 2005, Nucleic acids research.

[15]  A. Pardi,et al.  High-resolution molecular discrimination by RNA. , 1994, Science.

[16]  George Quick,et al.  Antidote-mediated control of an anticoagulant aptamer in vivo , 2004, Nature Biotechnology.

[17]  L. C. Bock,et al.  In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. , 1993, Blood.

[18]  C. Giancola,et al.  A new modified thrombin binding aptamer containing a 5′–5′ inversion of polarity site , 2006, Nucleic acids research.

[19]  B. Shen,et al.  Screening of functional antidotes of RNA aptamers against bovine thrombin , 2004, FEBS letters.

[20]  D. Monroe,et al.  Platelets and thrombin generation. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Penmetcha K. R. Kumar,et al.  Aptamer-derived nucleic acid oligos: applications to develop nucleic acid chips to analyze proteins and small ligands. , 2005, Analytical chemistry.

[22]  S. Gopinath,et al.  Snake-venom-derived Factor IX-binding protein specifically blocks the gamma-carboxyglutamic acid-rich-domain-mediated membrane binding of human Factors IX and X. , 2007, The Biochemical journal.

[23]  Itamar Willner,et al.  Nucleic acid-functionalized Pt nanoparticles: Catalytic labels for the amplified electrochemical detection of biomolecules. , 2006, Analytical chemistry.

[24]  S. Gopinath.  Methods developed for SELEX , 2006, Analytical and bioanalytical chemistry.

[25]  M. Mascini,et al.  Analytical applications of aptamers. , 2005, Biosensors & bioelectronics.

[26]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[27]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[28]  Andrew D Ellington,et al.  Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.

[29]  G. Mayer,et al.  A new anticoagulant-antidote pair: control of thrombin activity by aptamers and porphyrins. , 2007, Journal of the American Chemical Society.

[30]  B. Sullenger,et al.  Nucleic acid aptamers in therapeutic anticoagulation , 2005, Thrombosis and Haemostasis.

[31]  Jean-Luc Pellequer,et al.  Model of a Ternary Complex between Activated Factor VII, Tissue Factor and Factor IX , 2002, Thrombosis and Haemostasis.

[32]  M F Kubik,et al.  Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. , 1997, Journal of molecular biology.

[33]  Subash C B Gopinath,et al.  An RNA aptamer that discriminates bovine factor IX from human factor IX. , 2006, Journal of biochemistry.

[34]  Andrew D Ellington,et al.  Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.

[35]  M. Famulok,et al.  Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors. , 2005, Biosensors & bioelectronics.

[36]  Kevin W Plaxco,et al.  Aptamer-based electrochemical detection of picomolar platelet-derived growth factor directly in blood serum. , 2007, Analytical chemistry.

[37]  Wei-xing Li,et al.  A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation , 1994 .

[38]  An anticoagulant with light-triggered antidote activity. , 2006, Angewandte Chemie.

[39]  S. Steinhubl,et al.  First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.

[40]  B. Shen,et al.  RNA aptamers specific for bovine thrombin , 2003, Journal of molecular recognition : JMR.

[41]  B. Sullenger,et al.  Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa , 2000, Thrombosis and Haemostasis.